Acute myeloid leukemia (AML), with an incidence increasing with age, is the most common
acute leukemia in adults. Concurrent comorbidities, mild to severe organ dysfunctions, and …

Background Acute myeloid leukemia (AML) is a common leukemia subtype and has a poor
prognosis. The risk of AML is highly related to age. In the context of population aging, a …

Considerable progress has been made in the treatment of acute myeloid leukemia (AML).
However, current therapeutic results are still unsatisfactory in untreated high-risk patients …

Background. Leukemia is a common malignancy that has four main subtypes and is a threat
to human health. Understanding the epidemiological status of leukemia and its four main …

Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients
with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax …

For most acute myeloid leukemia (AML) patients an allogeneic hematopoietic stem cell
transplantation (HSCT) offers the highest chance of cure. The introduction of less toxic non …

Combinations of the BCL‐2 inhibitor, venetoclax, with either hypomethylating agents (HMA)
or low dose cytarabine (LDAC), have shown promising results in clinical trials of AML …

Allogeneic hematopoietic stem cell transplantation remains an important treatment modality
for patients with acute myeloid leukemia (AML). Recent advances have extended donor …

Background The correlation between sarcopenia and hematological malignancy prognosis
is still controversial. Design: A systematic review and meta-analysis. Objectives: To explore …

Venetoclax (VEN) plus a hypomethylating agent (HMA) regimen is the standard of care for
older adults with acute myeloid leukemia (AML); however, it is associated with significant …